BiotechTube

ADR-002K administration

Phase 1UNKNOWN
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

D017202

Conditions

D017202

Trial Timeline

Nov 27, 2019 → Oct 31, 2021

NCT ID
NCT04695522

About ADR-002K administration

ADR-002K administration is a phase 1 stage product being developed by Rohto Pharmaceutical for D017202. The current trial status is unknown. This product is registered under clinical trial identifier NCT04695522. Target conditions include D017202.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04695522Phase 1UNKNOWN

Other Products from Rohto Pharmaceutical

Mesenchymal stem cell + PlaceboPhase 2
52
Mesenchymal stem cell + PlaceboPhase 2
52
Mesenchymal stem cellPhase 1/2
41
UDI-001Phase 1/2
41
infusion of ADR-001 (Mesenchymal stem cell)Phase 1
33